The Boots Enterprise Zone

Total Page:16

File Type:pdf, Size:1020Kb

The Boots Enterprise Zone Project Promoter: Walgreens Boots Alliance The Boots Scale: £100m+ GDV Enterprise Zone Sector: Nottingham Mixed use Location: Opportunity Close to Nottingham City Centre The Boots Enterprise Zone has opportunities for commercial and residential development, and seeks Investment Type: investment and development proposals including Equity, debt and forward equity, debt and forward funding investment for funding investment for identified occupiers. identified occupiers The site offers a unique opportunity to co-locate next to one of the World’s leading brands, The Walgreens Planning Status: Boots Alliance. The driver is to secure new occupiers Outline permission granted and end-users through flexible investment structures. A new housing development on the site will provide an unprecedented place to live, work and play. Overview At present the campus provides a Data Centre, Research and Development Facilities, Manufacturing, Pharmaceutical Wholesale Background and Logistics functions. The site also houses Boots has a long and illustrious history MediCity – a joint venture with BioCity. with Nottingham – since humble MediCity offers the ideal environment for beginnings when John Boot opened a both start-up and established companies store in the City in 1849. The current 279 to develop. Businesses will not only benefit acre site was purchased in 1927 to expand from BioCity’s experience of successfully the business. The promoter Walgreens growing businesses in specialised incubator Boots Alliance are looking to share their environments but also from Boots values to help encourage healthier and expertise in the global healthcare sector, happier lives across the world. including access to innovation and product development knowledge, as well as supply The Boots Enterprise Zone project involves chain expertise. The existing Boots operation the redevelopment of c. 35 hectares of will remain on site. surplus land at the Boots site to create a centre of Health, Wellbeing and Beauty. In early 2018 a new road bridge and spine Outline Planning Consent was granted road was completed providing excellent in December 2014 for 82,000 sqm of access to the development land. In addition, commercial space. In addition there are the site entrance at the Beeston end of the plans to build up to 675 residential units, development has also been re-modelled creating a new urban village on the site. and is now operational. Land has been remediated and advanced talks are taking Project Description place with the first housing and commercial delivery partners. The site sits on the border of Nottingham City and Broxtowe Borough Project Promoter and Partnerships - approximately 3 miles to the West of Nottingham city centre. The site offers The project is being promoted by Innes a unique opportunity to build a complete England in partnership with Nottingham lifestyle option – live, work, enterprise and City Council and D2N2 Local Enterprise innovation all fully integrated in one place. Partnership. Nottingham.
Recommended publications
  • Contents Page
    Statement of Development Principles: Regeneration Of Boots Campus, Beeston, Nottingham June 2007 STATEMENT OF DEVELOPMENT PRINCIPLES: REGENERATION OF BOOTS CAMPUS, BEESTON, NOTTINGHAM (June 2007) Contents 1. Introduction................................................................................................2 PURPOSE.............................................................................................................................. 2 POLICY CONTEXT................................................................................................................ 3 2. Development Principles ............................................................................4 THE VISION........................................................................................................................... 4 KEY DEVELOPMENT PRINCIPLES ..................................................................................... 4 3. Key Issues ..................................................................................................7 HIGHWAYS AND ACCESS ................................................................................................... 7 BALANCE OF USES ............................................................................................................. 7 LISTED BUILDINGS .............................................................................................................. 9 ENVIRONMENT.....................................................................................................................9
    [Show full text]
  • All Together. Different. Svi Zajedno
    Diversity & Inclusion Report 2018–19 All Together. Different. Svi zajedno. Različiti. • Všichni společně. • Každý jiný. • Eensgezind. Anders. • Tous ensem- ble, tous différents. • Einträchtig. Anders. • Tut- ti assieme, ma diversi. • Visi kartu. Skirtingi. • Alle sammen. Forskjellige • Todos juntos. TableDifer of Contents- Deepening Our Diversity and Inclusion entes. • Împreună. Diferiți • Hep birlikte. FaEmphasisrklı. ............................................... 1 • Svi zajedno. Različiti. • Všichni společněMessages. • from Our CEO, Global Chief Human Resources Officer and Our Global Každý jiný. • Eensgezind. Anders. • Tous enChief -Diversity Officer ........................2–3 Our D&I Impact Is Expansive semble, tous différents. • Einträchtig. Anderand Expandings. • ...................................... 4 WBA Strengthens Its D&I Strategy, Tutti assieme, ma diversi. • Visi kartu. SkirtiData Collectionngi. ............................... 6–13 Our Business Resource Groups Foster Inclusive Global Cultures ................ 14–21 All Together. Different. Împreună. Diferiți • Expanding Business Opportunities Todos juntos. Diferentes. • Hep birlikte. Farklby Attracting,ı. Nurturing Diverse Suppliers .......................... 22–25 • Svi zajedno. Različiti. • Všichni společně.WBA • Earns Wide Recognition for D&I Leadership ........................ 26–27 Každý jiný. • Eensgezind. Anders. • Tous ensemLooking Ahead ....................................- 29 ble, tous différents. • Einträchtig. Anders. • Tut- ti assieme, ma diversi. • Visi kartu.
    [Show full text]
  • Corporate Social Responsibility Report 2016 Walgreens Boots Alliance Is the First Global Pharmacy-Led, Health and Wellbeing Enterprise
    Corporate Social Responsibility Report 2016 Walgreens Boots Alliance is the first global pharmacy-led, health and wellbeing enterprise. Our purpose is to help people across the world lead healthier and happier lives. Our 2016 Corporate Social Responsibility Report covers the fiscal year that ended 31 August 2016. In this year’s report: Overview Marketplace Introduction ...................................................1 Our CSR goals .............................................2 28 Our vision, purpose and values ................3 Our approach to CSR .................................4 Contributing to the United Nations Sustainable Development Goals .............6 Transparency ........................................... 30 Our impact ...................................................8 Ethical Sourcing ...................................... 30 ........................... About our Company ................................. 10 External Stakeholders 31 Stakeholder engagement ....................... 12 Workplace Community 32 14 Employee Health and Wellbeing ........ 34 Equal Opportunities .............................. 36 Health and Wellbeing ............................. 16 Health and Safety ...................................37 Young People ........................................... 17 ...................................... Cancer Programs .....................................20 About this report 38 Data management process ................ 38 Environment Data ............................................................ 38 Community data
    [Show full text]
  • At the Heart of Health Corporate Social Responsibility Report
    2020 At the Heart of Health Corporate Social Responsibility Report #WeAreWBA We are a leading global pharmacy retailer and wholesaler. As a health and well-being enterprise our purpose is to help people across the world lead healthier and happier lives. At the Heart of Health is our annual Corporate Social Responsibility report, covering our CSR initiatives, sustainability progress and Environmental, Social and Governance (ESG) performance for the fiscal year ended Aug. 31, 2020. OVERVIEW HEALTHY PLANET Message from Our Leaders 4 Energy and Emissions 85 Q&A with Our CSR Committee Chair 6 Waste and Plastics 94 Our Vision, Purpose and Values 8 Case Study: Honeybees on Campus 100 At a Glance: WBA 9 SUSTAINABLE MARKETPLACE Highlights and Recognitions 10 Progress Dashboard 12 Sustainability Progress in Our Owned Brands 103 Our Approach to CSR 15 Sourcing 106 CSR Materiality 24 Ingredients, Materials and Traceability 111 Stakeholder Engagement 28 Packaging, Labeling and Transparency 114 Our Response to COVID-19 38 Case Study: Removing Plastics from Boots UK Gift Product Lines 117 Our Response to the Racial Equity Movement 46 Brands with Purpose 118 HEALTHY AND INCLUSIVE WORKPLACE HEALTHY COMMUNITIES Employee Health, Well-being and Safety 123 Access to Affordable and Quality Healthcare 51 Equal Opportunities 134 Health Education and Awareness 61 Case Study: Unconscious Bias Training 145 Opioid Abuse Prevention 70 Data Privacy and Information Security 146 Partnerships for Good: 71 APPENDICES Supporting People Living with Cancer 72 About This Report
    [Show full text]
  • Distributor Settlement Agreement
    DISTRIBUTORS’ 7.30.21 EXHIBIT UPDATES DISTRIBUTOR SETTLEMENT AGREEMENT DISTRIBUTORS’ 7.30.21 EXHIBIT UPDATES Table of Contents Page I. Definitions............................................................................................................................1 II. Participation by States and Condition to Preliminary Agreement .....................................13 III. Injunctive Relief .................................................................................................................13 IV. Settlement Payments ..........................................................................................................13 V. Allocation and Use of Settlement Payments ......................................................................28 VI. Enforcement .......................................................................................................................34 VII. Participation by Subdivisions ............................................................................................40 VIII. Condition to Effectiveness of Agreement and Filing of Consent Judgment .....................42 IX. Additional Restitution ........................................................................................................44 X. Plaintiffs’ Attorneys’ Fees and Costs ................................................................................44 XI. Release ...............................................................................................................................44 XII. Later Litigating
    [Show full text]
  • At the Heart of Health Corporate Social Responsibility Report
    2020 At the Heart of Health Corporate Social Responsibility Report #WeAreWBA We are a leading global pharmacy retailer and wholesaler. As a health and well-being enterprise our purpose is to help people across the world lead healthier and happier lives. At the Heart of Health is our annual Corporate Social Responsibility report, covering our CSR initiatives, sustainability progress and Environmental, Social and Governance (ESG) performance for the fiscal year ended Aug. 31, 2020. OVERVIEW HEALTHY PLANET Message from Our Leaders 4 Energy and Emissions 85 Q&A with Our CSR Committee Chair 6 Waste and Plastics 94 Our Vision, Purpose and Values 8 Case Study: Honeybees on Campus 100 At a Glance: WBA 9 SUSTAINABLE MARKETPLACE Highlights and Recognitions 10 Progress Dashboard 12 Sustainability Progress in Our Owned Brands 103 Our Approach to CSR 15 Sourcing 106 CSR Materiality 24 Ingredients, Materials and Traceability 111 Stakeholder Engagement 28 Packaging, Labeling and Transparency 114 Our Response to COVID-19 38 Case Study: Removing Plastics from Boots UK Gift Product Lines 117 Our Response to the Racial Equity Movement 46 Brands with Purpose 118 HEALTHY AND INCLUSIVE WORKPLACE HEALTHY COMMUNITIES Employee Health, Well-being and Safety 123 Access to Affordable and Quality Healthcare 51 Equal Opportunities 134 Health Education and Awareness 61 Case Study: Unconscious Bias Training 145 Opioid Abuse Prevention 70 Data Privacy and Information Security 146 Partnerships for Good: 71 APPENDICES Supporting People Living with Cancer 72 About This Report
    [Show full text]
  • Boots Retail Profile
    Copyright © 2015 HPCi Media. This publication may not be distributed without prior permission. BOOTS RETAIL PROFILE BOOTS A CHANGE OF STRIDE Founded in 1849, Boots is a traditional staple of the British high street, yet the past decade has brought considerable changes for the health and beauty retailer. Annemarie Kruse reports Boots is the UK’s leading specialist health and beauty retailer. Operating 2,511 stores in the UK and Ireland with a total of 60,000 employees, Boots also has a large number of outlets in the Middle East, including UAE, Qatar, Kuwait, Bahrain and Saudi Arabia, in Asia, including Thailand, Singapore and Hong Kong and in Canada. Boots operates a multi-format strategy for its stores in the UK, with four main outlet types: local pharmacy healthcare-focused community stores; services and drug user services. Some stores also edge of town and high street health and beauty offer travel clinics, winter flu vaccinations, and in stores; flagship stores; and Boots airport stores, selected outlets welfare customers receive free which are tailored to travellers. Smaller Boots basic health check-ups. The chain also runs 600 stores carry a basic range of beauty brands and Boots Opticians stores in the UK, around 30% focus more on the convenience aspect, while the of which are located in Boots stores, while its larger outlets and flagship stores also offer hearing aid subsidiary, Boots Hearingcare, premium and niche brands and beauty halls with currently has 430 locations across the UK, many trained consultants. of which are situated within Boots Opticians In addition to the European and international outlets.
    [Show full text]
  • HEALTH + Registered Offi Ce Helping People Look Alliance Boots Gmbh and Feel Their Best Baarerstrasse 94 CH-6300 Zug Switzerland
    Alliance Boots Boots Alliance Annual Report 2010/11 Annual For more information www.allianceboots.com HEALTH + Registered offi ce Helping people look Alliance Boots GmbH and feel their best Baarerstrasse 94 CH-6300 Zug Switzerland Contact [email protected] Alliance Boots Annual Report 2010/11 Overview Our performance in 2010/11 Glossary of key terms (for the year ended 31 March 2011) Constant currency Like for like revenue Trading profit Exchange rates applicable for the financial Like for like revenue on a constant currency basis Profit from operations before amortisation of information for the year ended 31 March 2010. compared to the comparable period in the customer relationships and brands, exceptional previous year. items and share of post tax earnings of EBITDA associates and joint ventures. Trading profit before underlying depreciation Net borrowings Revenue EBITDA Trading profit and amortisation. Cash and cash equivalents, restricted cash, Underlying depreciation and amortisation derivative financial instruments and borrowings Depreciation and amortisation adjusted to Exceptional items net of unamortised prepaid financing fees. exclude amortisation of customer relationships Items classified by Alliance Boots as exceptional and brands and depreciation and amortisation in nature. These are not regarded as forming Net finance costs within exceptional items. +15.1% +10 . 8 % +14 . 2 % part of the underlying trading activities of the Finance costs net of finance income. Group and so merit separate presentation to Underlying net finance costs allow stakeholders to understand the elements Restricted cash Net finance costs adjusted to exclude of financial performance and assess trends in Cash which is restricted for specific purposes exceptional items and timing differences within financial performance.
    [Show full text]
  • WALGREENS BOOTS ALLIANCE, INC . (Exact Name of Registrant As Specified in Its Charter) Delaware 47-1758322 (State of Incorporation) (I.R.S
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2016 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From ____________ to ___________ Commission file number 001-36759 WALGREENS BOOTS ALLIANCE, INC . (Exact name of registrant as specified in its charter) Delaware 47-1758322 (State of incorporation) (I.R.S. Employer Identification No.) 108 Wilmot Road, Deerfield, Illinois 60015 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (847) 315-2500 Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Common Stock ($.01 Par Value) The NASDAQ Stock Market LLC 2.875% Notes due 2020 New York Stock Exchange 3.600% Notes due 2025 New York Stock Exchange 2.125% Notes due 2026 New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Title: the Rise and Rise of Biotech and Life Sciences in Nottingham Will Rossiter, David Smith, & Daniel Mcdonald-Junor
    Title: The rise and rise of biotech and life sciences in Nottingham Will Rossiter, David Smith, & Daniel McDonald-Junor, Nottingham Business School Notable in this years’ Top 200 list are an increasing number of local companies involved in the applications of biotechnology and life sciences – companies like Fresenius Medical , Source Bioscience Limited, and Robinsons Healthcare. Indeed this phenomenon has come to symbolise Nottingham’s reinvention as a post-industrial economy. Recent research at Nottingham Business School has started to explain how it happened. At the start of the millennium, Nottingham looked to be a city facing serious industrial decline. Former mainstays of the local economy like Raleigh, Players, and Royal Ordnance had ceased large scale manufacturing operations in the City and employment in the sector continued to shrink as the balance of the economy shifted towards the service sector. Move forward a decade or two however, and you’ll find a different story. A new development path has been forged through the application of biotechnology and life sciences. That this should have happened in a former manufacturing city in the North Midlands is remarkable. The most obvious symbol of this is BioCity, where more than 75 bioscience-related companies have been established since 2003. Although modest in scale by the standards of bioscience concentrations in London and the South East, the emergence of bioscience in Nottingham is significant. Not least because this momentum has been sustained over a 15-year timeframe and shows no signs of slowing. Indeed BioCity is now the country’s largest life science themed business incubation facility.
    [Show full text]
  • WALGREENS BOOTS ALLIANCE, INC. (Exact Name of Registrant As Specified in Its Charter)
    SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2021 WALGREENS BOOTS ALLIANCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36759 47-1758322 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification Number) 108 Wilmot Road, Deerfield, Illinois 60015 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (847) 315-2500 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934: Trading Name of each exchange Title of each class Symbol(s) on which registered Common Stock, $0.01 par value WBA The Nasdaq Stock Market LLC 3.600% Walgreens Boots Alliance, Inc. notes due WBA25 The Nasdaq Stock Market LLC 2025 2.125% Walgreens Boots Alliance, Inc.
    [Show full text]
  • Walgreens Boots Alliance Completes Strategic Transaction with Amerisourcebergen Divesting Alliance Healthcare Businesses
    Walgreens Boots Alliance Completes Strategic Transaction with AmerisourceBergen Divesting Alliance Healthcare Businesses 6/2/2021 Company deploying proceeds of $6.5 billion to pay down debt and boost strategic healthcare investments Extended and expanded commercial agreements to drive incremental growth and synergies DEERFIELD, Ill.--(BUSINESS WIRE)-- Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced it has completed the sale of its Alliance Healthcare businesses to AmerisourceBergen for total consideration of approximately $6.5 billion, made up of $6.275 billion in cash (subject to a customary net cash and working capital adjustment) and 2 million shares of AmerisourceBergen common stock. The company will use the cash proceeds to reduce debt and accelerate growth of its core retail pharmacy and healthcare businesses. The company has used a portion of the funds to repay the outstanding amount owed on a $3.8 billion term loan that funded the bond tender completed by the company on April 26, 2021. This has eliminated $3.3 billion in debt from the company’s balance sheet. The remaining net cash proceeds are planned to be invested in strategic opportunities and to expand healthcare oerings to help accelerate the company’s growth strategy. These investments will further build on previously announced initiatives, including WBA’s investment in VillageMD to support the opening of 600-700 Village Medical at Walgreens primary care clinics, as well as WBA’s acquisition of a majority stake in iA, a leading-edge provider of software-enabled pharmacy automation solutions. “Completion of this transaction represents a signicant step forward in our transformation and will fuel investments to grow WBA’s core retail pharmacy and healthcare businesses,” said Rosalind Brewer, CEO, Walgreens Boots Alliance.
    [Show full text]